In agreement with the data here reported, ERβ agonists, as well as phytoestrogens (such as apigenin, resveratrol) have been shown to arrest breast cancer cell growth by causing a cell cycle arrest, through the regulation of cell cycle-related proteins, such as cyclin D1 and the CDK inhibitors p21 and p27 [60–62]; more recently, it has been reported that preferential ERβ ligands reduce the expression of the antiapoptotic protein Bcl-2 to increase autophagy in hormone-resistant breast cancer cells [63]. Here, CDKN1B is linked to breast carcinoma.